Therapeutics that target DNA DSB signaling and DNA repair mechanisms
Mitra et al. have shown that depletion of TDP-43 is associated with an increase in double strand break (DSB) signaling. TDP-43 serves as a scaffold for DNA DSB factors, and the aberrant mislocalization of this protein feasibly contributes to genomic instability and the pronounced motor-neuron cell death that is a prominent hallmark evidenced in ALS. Targeting the DNA repair response as an ALS therapeutic is a novel rationale therapeutic app.
Immunosuppressants in the treatment of ALS though modulation of TDP-43
Introduction see: \cite{Fournier_2018}
Rapamycin: Rapamycin inhibitor of the Mechanistic Target of Rapamycin (mTOR) is a clinically approved drug prescribed in cancer therapeutics \cite{Apontes2011}, and for the prevention of organ rejection via its immunosuppressant functions (ref). Autophagy an important cell process for protein turnover and degradation of aberrant proteins is upregulated by rapamycin. Rapamycin also downregulates protein synthesis, inhibits inflammatory responses, and has demonstrated efficacy in animal models of neurodegenerative. Rapamycin was shown in vitro in N2A and SH-SY5Y cells to induce autophagy, decrease TDP-43 aggregates, and correct the mislocalization of TDP-43 from the cytoplamic aggregation to restore it to the nucleus \cite{Caccamo_2009}. The clearance of TDP-43 by autophagy has been demonstrated in murine and in human stem cell-derived neurons and astrocytes with mutant TDP43 \cite{Barmada_2014}. The rapamycin for amyotrophic lateral sclerosis trial (RAP-ALS trial) is in a phase II randomized, double-blind, placebo-controlled, and multicenter trial with patients randomized to one of three groups: 1 mg/m2/d + riluzole, 2 mg/m2/d + riluzole or placebo and riluzole \cite{Mandrioli_2018}. The treatment of ALS with  Ramamycin with the aim of modulation of TDP-43 clearance and correction of cytoplasmic mislocalization will be important novel therapeutic approach to follow. 
Basiliximab: 20 mg, IV (in the vein) on day 1 and 4.